Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib in Adults with Moderate to Severe Hidradenitis Suppurativa
2025-522705-37-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Ritlecitinib with Placebo (2 arms). Primary endpoint: HiSCR50 response at Week 16. Planned start Mar 2026; status: authorised.
02
Drugs
ritlecitinib tosilate
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2025-522705-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522705-37-00.